// Xing-Kang He 1, 2, * , Yue Ding 1, 2, * and Lei-Min Sun 1, 2 1 Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University Medical School, Hangzhou 310016, China 2 Institute of Gastroenterology, Zhejiang University, Hangzhou 310016, China * These authors contributed equally to this work Correspondence to: Lei-Min Sun, email: sunleimin@yahoo.com Keywords: contrast-enhanced EUS, contrast-enhanced doppler EUS, contrast-enhanced harmonic EUS, pancreatic adenocarcinomas Received: July 10, 2016 Accepted: June 18, 2017 Published: July 01, 2017 ABSTRACT Aim: We aim to assess the diagnostic value of contrast-enhanced endoscopic ultrasound (CE-EUS) for pancreatic cancer and inflammatory lesions by pooling current evidence. Materials and Methods: A systematical search of PubMed, Web of Science and the Cochrane Library was performed from inception to January 2016. Two authors independently screened and extracted detailed data from included studies. A random effect model was adopted to estimate the pooled sensitivity, specificity in order to determine the diagnostic ablitity of CE-EUS. Furthermore, we conducted the meta-regression and subgroup analyses to explore possible heterogeneity. Results: Eighteen eligible studies enrolling 1668 patients were finally included in the study. The pooled sensitivity of CE-EUS for distinguishing pancreatic cancers from solid inflammatory masses was 0.93 (95% CI, 0.91–0.94), and the specificity was 0.88 (95% CI, 0.84–0.90). The area under summary receiver operating characteristic curve yielded 0.97. No publication bias was observed by Deeks’ funnel plot in current meta-analysis. Conclusions: We provided evidence that CE-EUS is a promising modality for differential diagnosis of pancreatic adenocarcinomas. Further multicenter prospective studies should be carried out to certify its utility.
No takes yet. Share an insight, caveat, or question.
He et al. (2017) studied this question.